Sex: U
Vaccine: COVID19
Symptoms: Myalgia, Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest; Significant injection site redness; Significant injection site swelling; Moderate fever (101.3 to 102 °F); Moderate fatigue with some interference with activity; Severe muscle pain significantly interfering with activity; Joint pain with some interference with activity; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting; Headache that interfered with activity OR required repeated use of a nonprescription pain reliever; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Significant injection site swelling) and PYREXIA (Moderate fever (101.3 to 102 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Significant injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain with some interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), VACCINATION SITE PAIN (Significant injection site pain preventing daily activity/Significant injection site tenderness (tenderness during rest), VACCINATION SITE ERYTHEMA (Significant injection site redness), VACCINATION SITE SWELLING (Significant injection site swelling), PYREXIA (Moderate fever (101.3 to 102 °F)), FATIGUE (Moderate fatigue with some interference with activity), MYALGIA (Severe muscle pain significantly interfering with activity), ARTHRALGIA (Joint pain with some interference with activity), VOMITING (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting), NAUSEA (Mild nausea/vomiting and no interference with activity or 1-2 episodes of nausea/vomiting) and HEADACHE (Headache that interfered with activity OR required repeated use of a nonprescription pain reliever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: Moderate fever (101.3 to 102 °F).     The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Unknown) was unknown.       Patient had experienced malaise, vaccination site pain, vaccination site erythema, vaccination site swelling, pyrexia, fatigue, myalgia, arthralgia, nausea, vomiting and headache anytime during the 2 days after your COVID-19 vaccination, which occurred on Thursday, Dec 21, 2023 and Friday, Dec 22, 2023.  The Subject ID was reported.  The Subject ID was reported.  Concomitant medications were not reported.  No treatment information was provided by the reporter.   This case was linked to US-MODERNATX, INC.-MOD-2024-756099 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756099:Master case